Portal de Periódicos da CAPES

Artigo Produção Nacional Revisado por pares

BIBTEX RIS

Breast Cancer Quality of Life and Health-state Utility at a Brazilian Reference Public Cancer Center

2019; Taylor & Francis; Volume: 20; Issue: 2 Linguagem: Inglês

10.1080/14737167.2019.1621752

1744-8379

Renata Leborato Guerra, Neilane Bertoni, Flávia de Miranda Corrêa, Myrian Machado Fernandes, Ricardo Ribeiro Alves Fernandes, Marianna de Camargo Cancela, Rodrigo Moura de Araújo, Susanne Crocamo, Marisa Santos, Liz Maria de Almeida,

Global Cancer Incidence and Screening

Objectives: To evaluate health-related-quality-of-life and derive health-state-utility (HSU) from breast cancer patients, before and after routine therapy at a Brazilian reference public cancer center.Methods: In a prospective cohort study, a consecutive sample of outpatients newly diagnosed with breast cancer was submitted to two interviews (baseline, 6-month) to complete EQ-5D-3L/VAS and EORTC-QLQ-C30/BR23 questionnaires. Demographic and clinical information was reviewed from medical records.Results: For 196 patients, EQ-5D domains of pain/discomfort and anxiety/depression were mainly affected, but partially improved overtime, while mobility/usual activities/self-care worsened after therapy. EORTC-QLQ-C30/BR23 scales mostly affected were emotional functioning, insomnia, pain, sexual enjoyment and future self-health perspective at baseline, while financial difficulties, insomnia, fatigue and therapy side-effects at follow-up. Overtime mean scores were 71.4 (95%CI68.5–74.4) and 76.1 (95%CI73.3–78.8) for EQ-5D-VAS, and 0.712 (95%CI0.686–0.737) and 0.732 (95%CI0.707–0.757) for HSU. HSU was 0.689 (95%CI0.648–0.730) in stages III-IV, and 0.692 (95%CI0.652–0.731) under two/three chemotherapy regimens.Conclusion: In a context of impairments in emotional functioning, sexual enjoyment, symptoms burden, and poor future self-health perspective, breast cancer produced a mean HSU of 0.712. After routine care, there was a small improvement in quality of life, with lower HSU particularly in advanced disease and multiple chemotherapy regimens.